The impact of indacaterol/glycopyrronium fixed-dose combination versus tiotropium monotherapy on lung function and treatment preference: a randomized crossover study - the FAVOR study.

ABSTRACT:

Background

The objective of the FAVOR study was to evaluate the effect of indacaterol/glycopyrronium (IND/GLY) versus tiotropium on peak forced expiratory volume in 1 s (FEV₁) and also to investigate patient satisfaction and treatment preference.

Methods

Patients with moderate-to-severe airflow limitation (FEV₁/forced vital capacity ratio of <0.70), those with a COPD assessment test score of ≥10, and those who were maintained on tiotropium HandiHaler^® therapy prior to enrollment were recruited for the study, and randomized (1:1) to receive either 4 weeks open-label IND/GLY (110/50 μg) once daily followed by 4 weeks of tiotropium (18 μg) once daily or vice versa. The primary endpoint was FEV₁ 1 h post-inhalation after 4 weeks of tre

SUBMITTER: Kardos P 

PROVIDER: S-EPMC5744738 | biostudies-literature | 2018

REPOSITORIES: biostudies-literature